More recent meta-analyses of treatments adjunctive to levodopa in advanced PD have confirmed the capacities of oral IR dopamine agonists, COMT inhibitors, and MAO-B inhibitors to reduce “OFF” time and UPDRS scores. Here, COMT is linked to Parkinson disease.